Skip to main content

Advertisement

Table 1 Characteristics of rivaroxaban patients

From: Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study

No Sex, age (years) Weight (kg) BMI (kg/m2) CLcr (ml/min) Hb (g/dl) Indication Dosage Duration CHA2DS2-VASC HAS-BLED
1 M, 83 79 23.1 58 13.7 SPAF 20 mg OD ≤ 1 year 5 3
2 F, 70 N/K N/K N/K 3.1 SPAF 15 mg OD >  1 year 3 1
3 F, 87 65 25.7 48 6.4 VTE 20 mg OD <  30 days N/A 2
4 F, 67 80 24.7 53 7.2 SPAF 20 mg OD >  1 year 6 2
5 F, 77 63 25.2 61 14.3 SPAF 15 mg OD >  1 year 7 3
6 M, 66 100 35 86 15.6 SPAF 20 mg OD ≤ 1 year 2 2
7 F, 72 66 21.6 46 12.8 VTE 20 mg OD >  1 year N/A 3
8 F, 90 70 N/K 60 13.8 SPAF 15 mg OD N/K 6 1
9 F, 86 89 31.2 57 14.9 VTE 15 mg BID <  30 days N/A 1
10 F, 69 73 26.8 76 11.3 VTE 20 mg OD >  1 year N/A 2
  1. BID twice-daily, BMI body mass index, CLcr creatinine clearance (Cockroft-Gault equation), Hb haemoglobin, OD once-daily, N/A not applicable, N/K not known, SPAF stroke prevention in atrial fibrillation, VTE venous thromboembolism